Olmsted Medical Center:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Olmsted Medical Center - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9330
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Olmsted Medical Center (OMC) is a healthcare service provider that offers patient care services. The center offers services in the areas of general surgery, podiatry, pain management, dermatology, plastic surgery, inpatient dietary services, pediatrics, diabetes education, neurology, psychiatry, psychology, nutrition education and weight loss surgery, among others. It also offers birth center, laboratory services, radiology, diagnostic imaging, rheumatology, endocrinology, rehabilitation services, ENT, respiratory therapy, emergency medicine, audiology, anticoagulation clinic and others. The center operates in Chatfield, St Charles, Cannon Falls, Byron, Preston, Spring Valley and others. OMC is headquartered in Rochester, Minnesota, the US.

Olmsted Medical Center – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Olmsted Medical Center, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deal Details 9
Debt Offering 9
Olmsted Completes Public Offering Of Series 2010 Bonds Due 2020 For US$4.2 Million 9
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2015 For US$0.5 Million 10
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2016 For US$0.63 Million 11
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2017 For US$0.65 Million 12
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2018 For US$0.68 Million 13
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2019 For US$0.71 Million 14
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2020 For US$0.75 Million 15
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2021 For US$0.79 Million 16
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2022 For US$0.83 Million 17
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2023 For US$0.87 Million 18
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2024 For US$0.9 Million 19
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2025 For US$0.9 Million 20
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2026 For US$0.96 Million 21
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2027 For US$0.99 Million 22
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2028 For US$1.04 Million 23
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2029 For US$1.1 Million 24
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2033 For US$4.9 Million 25
Olmsted Medical Center – Key Competitors 26
Olmsted Medical Center – Key Employees 27
Olmsted Medical Center – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Olmsted Medical Center, Pharmaceuticals & Healthcare, Key Facts 2
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Olmsted Medical Center, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
Olmsted Completes Public Offering Of Series 2010 Bonds Due 2020 For US$4.2 Million 9
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2015 For US$0.5 Million 10
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2016 For US$0.63 Million 11
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2017 For US$0.65 Million 12
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2018 For US$0.68 Million 13
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2019 For US$0.71 Million 14
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2020 For US$0.75 Million 15
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2021 For US$0.79 Million 16
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2022 For US$0.83 Million 17
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2023 For US$0.87 Million 18
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2024 For US$0.9 Million 19
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2025 For US$0.9 Million 20
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2026 For US$0.96 Million 21
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2027 For US$0.99 Million 22
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2028 For US$1.04 Million 23
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2029 For US$1.1 Million 24
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2033 For US$4.9 Million 25
Olmsted Medical Center, Key Competitors 26
Olmsted Medical Center, Key Employees 27
Olmsted Medical Center, Other Locations 28
Olmsted Medical Center, Subsidiaries 29

List of Figures
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

★海外企業調査レポート[Olmsted Medical Center:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Buck Institute for Research on Aging-製薬・医療分野:企業M&A・提携分析
    Summary Buck Institute for Research on Aging (Buck Institute) is a healthcare institute that conducts research and offers educational services. The institute concentrates on understanding the connection between aging and chronic disease. It works to understand how normal aging contributes to the dev …
  • Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (874):製薬・医療:M&Aディール及び事業提携情報
    Summary Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (Guangzhou Baiyunshan Pharmaceutical) is a manufacturer of herbal medicine, chemical raw material medicine and preparation, biological medicine, and health products. The company also offers herbal tea, Chinese and Western medicine, intermed …
  • BorgWarner Inc.:企業の戦略・SWOT・財務情報
    BorgWarner Inc. - Strategy, SWOT and Corporate Finance Report Summary BorgWarner Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Synchrony Financial:企業の戦略・SWOT・財務分析
    Synchrony Financial - Strategy, SWOT and Corporate Finance Report Summary Synchrony Financial - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Spectra Energy Partners LP (SEP):石油・ガス:M&Aディール及び事業提携情報
    Summary Spectra Energy Partners LP (Spectra Energy), a subsidiary of Enbridge Inc., is a master limited partnership operating in mid-stream energy. The company conducts transmission, storage and gathering of natural gas. It also carries out the transportation and storage of crude oil. Spectra Energy …
  • SunPower Corporation (SPWR)-エネルギー分野:企業M&A・提携分析
    Summary SunPower Corporation (SunPower), a subsidiary of Total Energies Nouvelles Activites USA, is a provider of solar technology and energy services. The company has a presence in solar value chain from cell and panel manufacturing, project development, project finance through engineering, procure …
  • Liquid Media Group Ltd:企業の戦略・SWOT・財務分析
    Liquid Media Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Liquid Media Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Fronius International GmbH:企業の戦略的SWOT分析
    Fronius International GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Nice Ltd (NICE):企業の財務・戦略的SWOT分析
    Nice Ltd (NICE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Dampier Gold Limited:企業の戦略・SWOT・財務情報
    Dampier Gold Limited - Strategy, SWOT and Corporate Finance Report Summary Dampier Gold Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • REV Group, Inc. (REVG):企業の財務・戦略的SWOT分析
    REV Group, Inc. (REVG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Raia Drogasil SA:企業の戦略・SWOT・財務分析
    Raia Drogasil SA - Strategy, SWOT and Corporate Finance Report Summary Raia Drogasil SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Median Technologies SA (ALMDT):企業の財務・戦略的SWOT分析
    Summary Median Technologies SA (Median) is a medical technology company that develops and markets medical imaging solutions. The company offers clinical trials, imaging services for CT, scientific consulting, image and clinical data management, image data processing and site support, managed service …
  • The Jim Pattison Group:企業の戦略・SWOT・財務情報
    The Jim Pattison Group - Strategy, SWOT and Corporate Finance Report Summary The Jim Pattison Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Valeant Canada LP:製薬・医療:M&Aディール及び事業提携情報
    Summary Valeant Canada LP (Valeant Canada), a subsidiary of Valeant Pharmaceuticals International Inc, is a pharmaceutical products manufacturing company. The company offers products such as aczone, airomir, aldara, benzaclin topical gel, benzamycin, biacna topical gel, C.E.S. tablets, carbolith, ca …
  • Glory Ltd:企業の戦略・SWOT・財務情報
    Glory Ltd - Strategy, SWOT and Corporate Finance Report Summary Glory Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • EWE AG:企業の戦略的SWOT分析
    EWE AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Corcept Therapeutics Inc (CORT):企業の財務・戦略的SWOT分析
    Corcept Therapeutics Inc (CORT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Aushon BioSystems Inc:医療機器:M&Aディール及び事業提携情報
    Summary Aushon BioSystems Inc (Aushon) is a medical device provider that provides biomarker measurement and analysis products. The company offers biomarker therapeutic areas in microarray printing technology. It provides products such as ciraplex assay, cirascan imaging and cirasoft analysis and cir …
  • Xped Ltd (XPE):石油・ガス:M&Aディール及び事業提携情報
    Summary Xped Ltd (Xped) formerly Raya Group Limited, is an Internet of Things company that develops software and hardware solutions. It offers auto discovery remote control, Xerts, and Xped app software; and hardware such as Xped ADRC Shields, Umbo-Xped ADRC Hub, UltraPlug, VariPlug, IRBlaster. The …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆